-15%

est. 2Y upside i

HealthcareSeries D+

Rank

#2646

Sector

Medical Devices & Digital Health

Est. Liquidity

~4Y

Data Quality

Data: Low

This is a high-risk equity opportunity.

Last updated: July 21, 2026

Bull (10%)+50%

AliveCor successfully navigates Apple patent dispute, expands Kardia 12L in Europe and US, and achieves 20% revenue growth. Exit multiple holds at 5x, leading to ~50% upside but diluted by 20%.

Base (50%)-20%

Stagnant revenue growth due to Apple competition and slow enterprise adoption. Preference stack (68% of valuation) eliminates common equity value, resulting in -20% return after dilution.

Bear (40%)-100%

Patent invalidation leads to revenue decline, no funding raise, and exit below $318M. Common stock recovers -100% as liquidation preference consumes all proceeds.

Est. time to liquidity~4.0 years

Preference Stack Risk

severe

Funding Intensity

6800%

Total funding of $318M is 68% of the $467M valuation, meaning preferred shareholders have a large claim on exit proceeds.

Dilution Risk

high

The company has not raised since 2022, and with a likely cash burn, a down round or significant dilution is probable within 2 years.

Secondary Liquidity

none

No secondary market activity reported; shares are illiquid until a liquidity event.

Other — 2 roles

View all 2 open roles at Alivecor →

Last updated: February 22, 2026

Questions to Ask at the Interview

Strategic questions based on Alivecor's data — designed to show you've done your homework.

  • 1

    “How does AliveCor plan to compete with Apple's integrated health features?”

  • 2

    “What is the current revenue run rate and growth trajectory?”

  • 3

    “What is the expected timeline to liquidity (IPO or acquisition) and how will dilution affect employee equity?”

Community

Valuation Sentiment

Our model estimates -15% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.